192332-47-1

Upstream product

• 874-90-8 4-methoxybenzonitrile 

Downstream Products

• 949-02-0 C₁₀H₁₂N₂O₃ 
• 108-95-2 phenol 
• 102151-70-2 4-Carbomethoxy-2-(p-methoxyphenyl)imidazole 
• 40019-25-8 ethyl 3-(4-methoxyphenyl)-1,2,4-oxadiazole-5-carboxylate 
• 5311-71-7 methyl 4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl ether 

Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of novel oxadiazole- and thiazole-based histamine H3R ligands

Histamine H3 receptor (H3R) is largely expressed in the CNS and modulation of the H3R function can affect histamine synthesis and liberation, and modulate the release of many other neurotransmitters. Targeting H3R with antagonists/inverse agonists may have therapeutic applications in neurodegenerative disorders, gastrointestinal and inflammatory diseases. This prompted us to design and synthesize azole-based H3R ligands, i.e. having oxadiazole- or thiazole-based core structures. While ligands of oxadiazole scaffold were almost inactive, thiazole-based ligands were very potent and several exhibited binding affinities in a nanomolar concentration range. Ligands combining 4-cyanophenyl moiety as arbitrary region, para-xylene or piperidine carbamoyl linkers, and/or pyrrolidine or piperidine basic heads were found to be the most active within this series of thiazole-based H3R ligands. The most active ligands were in silico screened for ADMET properties and drug-likeness. They fulfilled Lipinski's and Veber's rules and exhibited potential activities for oral administration, blood–brain barrier penetration, low hepatotoxicity, combined with an overall good toxicity profile.

2-Amino-4-aryl thiazole: A promising scaffold identified as a potent 5-LOX inhibitor

Human 5-lipoxygenase (5-LOX) is an important enzyme in the biosynthesis of leukotrienes and is a target for asthma and allergy treatment. Zileuton is the only drug currently marketed that targets this enzyme (IC50 ～ 1 μM). So, the development of novel lead compounds is highly desirable. A series of 2-aryl indole, thiazolopyrazole acid, oxadiazolobenzothiophene, 1,4-disubstituted-1,2,3-triazole, 2-amino-4-aryl thiazole and 4,4′-(1,4-phenylene)bis(1,3-thiazole) derivatives when tested against this enzyme resulted in the identification of a potent compound (1d), p-fluoro substituted 2-amino-4-aryl thiazole, with an IC50 of ～10 μM. Another lead compound identified is (4a), a thiazolopyrazole acid derivative (IC50 ～ 40 μM). All the compounds exhibit poor DPPH radical scavenging activity which suggests that their action occurs not due to the disruption of the redox cycle of iron present in the enzyme (unlike zileuton) but through competitive inhibition, since the Vmax remains constant but the Km increases with an increase in inhibitor concentration. Molecular docking of 1d and 4a to the active site of 5-LOX also supports the experimental data, and suggests that their possible mechanism of action is through competitive inhibition. The current study identifies a promising lead molecule which could be improved further to match the activity of the commercial drug.

Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof

The present invention is directed to substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs thereof, represented by the Formula I: wherein Ar1, Ar3, A, B and D are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

Synthesis of 3,5-disubstituted-1,2,4-oxadiazoles using tetrabutylammonium fluoride as a mild and efficient catalyst

Tetrabutylammonium fluoride (TBAF) was found to be a mild and efficient catalyst for the synthesis of 3,5-disubstituted-1,2,4-oxadiazoles. Using 0.1 - 1.0 equivalents of TBAF in THF for 1 - 24 h at room temperature, alkanoyl- and aroyloxyamidines were converted in high yield to the corresponding 3,5-disubstituted-1,2,4-oxadiazoles. A variety of R and R′ substituents were investigated.

Phenoxy- and phenoxyalkyl-piperidines as antiviral agents

Compounds of the formula STR1 wherein R1 is selected from STR2 Y is a bond or lower alkylene; R2 and R3 are independently hydrogen, lower-alkyl or halogen; R4 is STR3 R5 is hydrogen, lower-alkyl or halogen; R6 is hydrogen, lower-alkyl or halogen; R7 is hydrogen or lower-alkyl; R8 is hydrogen, lower-alkyl, or trifluoromethyl; R9 is lower-alkyl; R10 is lower-alkyl, trifluoromethyl or difluoromethyl; or pharmaceutically acceptable acid addition salts thereof are useful as antiviral agents.

Oxadiazolyl benzamides

Substituted or unsubstituted oxadiazolyl benzamides, e.g., o-(3-phenyl-1,2,4-oxadiazol-5-yl)-N-methyl-benzamide, are prepared by reacting a corresponding substituted or unsubstituted oxadiazoyl benzoic acid alkyl ester with an amine and are useful as minor tranquilizers and sleep inducers.